3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Mastocytosis
1
Liver Neoplasms
1
Gastroenteropancreatic Neuroendocrine Tumors
1
GATA2 Deficiency
1
Colorectal Neoplasms
1
Advanced Solid Tumor
1
Interventions
Fluorouracil
5
Oxaliplatin
4
Surgical Procedures, Operative
3
Radiotherapy
3
Neoadjuvant Therapy
3
Leucovorin
3
Drug Therapy
3
Chemoradiotherapy
3
Capecitabine
3
Irinotecan
2
Immune Checkpoint Inhibitors
2
Folfox protocol
2
Bevacizumab
2
sulindac sulfone
1
sintilimab
1
XELOX
1
Water
1
Surveys and Questionnaires
1
Preoperative Exercise
1
Photochemotherapy
1
N-dihydrogalactochitosan
1
Microwaves
1
Mental Status and Dementia Tests
1
Magnetic Resonance Spectroscopy
1
Leucine-tRNA Ligase
1
Injections
1
Indocyanine Green
1
In Situ Hybridization, Fluorescence
1
Immunohistochemistry
1
HMPL-013
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Rectal Neoplasms
×
Injections
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled